Enanta Pharmaceuticals (ENTA) Common Equity (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Common Equity came in at $116.6 million in Q1 2026, up 24.64% YoY from $93.5 million in Q1 2025, and down 7.9% on a QoQ basis from $126.6 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Common Equity (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Common Equity data on file, last reported at $116.6 million in Q1 2026.
- Quarterly Common Equity rose 24.64% year-over-year to $116.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.6 million (up 24.64% YoY) and the FY2025 annual result came in at $64.7 million, down 49.76% from the prior year.
- Common Equity slipped to $116.6 million in Q1 2026, from $126.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $358.6 million in Q1 2022 to a low of $64.7 million in Q3 2025.
- A 5-year average of $192.4 million and a median of $166.1 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity sank 49.76% — and 2026, when it increased 24.64%.
- Tracing ENTA's Common Equity over 5 years: stood at $300.8 million in 2022, then sank by 36.22% to $191.9 million in 2023, then sank by 41.73% to $111.8 million in 2024, then grew by 13.21% to $126.6 million in 2025, then fell by 7.9% to $116.6 million in 2026.
- The last three Common Equity figures came in at $116.6 million (Q1 2026), $126.6 million (Q4 2025), and $64.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 101.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101.07 Mn |
| Mar 31, 2026 | 116.59 Mn |
| Dec 31, 2025 | 126.59 Mn |
| Sep 30, 2025 | 64.72 Mn |
| Jun 30, 2025 | 79.28 Mn |
| Mar 31, 2025 | 93.54 Mn |
| Dec 31, 2024 | 111.82 Mn |
| Sep 30, 2024 | 128.81 Mn |
| Jun 30, 2024 | 148.92 Mn |
| Mar 31, 2024 | 166.11 Mn |
| Dec 31, 2023 | 191.88 Mn |
| Sep 30, 2023 | 216.74 Mn |
| Jun 30, 2023 | 237.82 Mn |
| Mar 31, 2023 | 269.38 Mn |
| Dec 31, 2022 | 300.84 Mn |
| Sep 30, 2022 | 321.33 Mn |
| Jun 30, 2022 | 338.02 Mn |
| Mar 31, 2022 | 358.58 Mn |
| Dec 31, 2021 | 384.38 Mn |
| Sep 30, 2021 | 399.43 Mn |